Pharos iBio to Participate in 'Bio Korea 2026'... Showcasing AI Drug Discovery Platform

CSO Jongcheol Chae to Join Panel Discussion as an Expert in AI-Driven Drug Discovery

Pharos iBio, a company specializing in artificial intelligence (AI)-powered drug discovery, announced on the 29th that it is participating in "Bio Korea 2026," which is being held at COEX in Seoul until April 30. The company will showcase its AI and quantum computing-based research technologies and key achievements during the event.

Pharos I Bio booth set up at Bio Korea 2026 held at COEX, Seoul. Pharos I Bio

During the event, Pharos iBio has set up a dedicated booth to present its proprietary AI drug discovery platform, Chemiverse®, as well as its major pipelines. The company will also hold partnership meetings with global collaborators. On the 29th, Chief Scientific Officer (CSO) Jongcheol Chae will join a session titled "Changes in Drug Discovery Paradigms Driven by the Spread of AI and Quantum Computing Technologies" as a panelist, where he plans to discuss strategies for improving the efficiency of drug development using AI platforms and approaches to identifying new drug candidates.

CSO Chae is a quantum computing expert leading the advancement of Chemiverse at Pharos iBio. In this session, he will also share insights on the productivity and economic efficiency of R&D in AI-driven drug discovery, as well as achievements in pipeline optimization using Chemiverse.

Pharos iBio's leading pipelines include "Lasmotinib," a treatment for acute myeloid leukemia (AML); "PHI-501," a therapy for refractory solid tumors; and "PHI-601," a next-generation menin inhibitor. Lasmotinib, a therapy targeting FLT3 mutations, demonstrated safety and efficacy in its global Phase 1 clinical trial and is now preparing to enter a global Phase 2 trial. The company explained that there is confirmed synergy potential, as the anti-cancer efficacy increases when Lasmotinib is combined with a menin inhibitor.

PHI-501 is an oral solid tumor therapy currently under development, designed to simultaneously inhibit BRAF and DDR1/2, which are key signaling pathways in cancer cells. PHI-601 is an anti-cancer drug candidate from the menin inhibitor class.

Kyutae Kim, Head of Business Development at Pharos iBio, stated, "Bio Korea is a venue where you can get a comprehensive view of the latest technological trends and research directions in the global bio-health industry. Through our participation this year, we aim to actively pursue open innovation opportunities, further advance drug discovery, and accelerate the expansion of global partnerships."

This content was produced with the assistance of AI translation services.